Bone Cancer - Clinical Trials - October 2011

	A	B	C	D	E	F	G	H	I
1	CLINICAL TRIALS
2	BONE CANCER
3	Source: clinicaltrials.gov
4
5	ICAN advises every patient and other interested person, after reviewing this clinical trials spreadsheet, to check out clinical trials directly at www.cancer.gov in case there are updates since the date of this posting. ICAN does not purport to provide medical advice or to indicate which trial is suitable for a certain patient. Please consult your medical oncology team and the principal investigator in charge of the trial in which you are interested for information most relevant to your specific medical situation and decision-making process.
6						Contact Information
7	No.	Link	Official Title	Purpose	Citation	Organization/Sponsor	Collaborator	Status	Criteria

8
9	1	http://clinicaltrials.gov/ct2/show/NCT00020566	European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99)	This randomized phase III trial is studying different combination chemotherapy regimens to see how well they work when given with or without peripheral stem cell transplantation, radiation therapy, and/or surgery in treating patients with Ewing's sarcoma.	http://clinicaltrials.gov/ct2/show/NCT00020566 - Retrieved October 2011	University Hospitals, Leicester	National Cancer Institute; Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer - EORTC; Gesellschaft fur Padiatrische Onkologie und Hamatologie-Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie-Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group	Currently recruiting	Primary Bone Cancer-Stage IV; Osteosarcoma-Stage IV
10	2	http://clinicaltrials.gov/ct2/show/NCT00084695	The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells	This phase II trial is studying how well umbilical cord blood works as a source of stem cells in treating patients with types of cancer as well as other diseases.	http://clinicaltrials.gov/ct2/show/NCT00084695 - Retrieved October 2011	Milton S. Hershey Medical Center		Currently recruiting	Ewing's Sarcoma
11	3	http://clinicaltrials.gov/ct2/show/NCT00089245	Phase I Study Of Intrathecal Radioimmunotherapy Using I-8H9 For Central Nervous System/Leptomeningeal Neoplasms	This phase I trial is studying the side effects and best dose of radiolabeled monoclonal antibody therapy in treating patients with refractory, recurrent, or advanced CNS or leptomeningeal metastases.	http://clinicaltrials.gov/ct2/show/NCT00089245 - Retrieved October 2011	Memorial Sloan-Kettering Cancer Center	National Cancer Institute	Currently recruiting	Ewing's Sarcoma
12	4	http://clinicaltrials.gov/ct2/show/NCT00132158	A Dose Finding Study (Phase I) of the Combination of ZD1839 (Iressa®) and an Oral Formulation of Irinotecan (Camptosar™) in Children With Refractory Solid Tumors	The purpose of this Phase I study is to find the largest dose of the drug irinotecan, in combination with ZD1839, that can be given safely to children and to learn the good and bad effects. Studies performed in the laboratory have shown that ZD1839 helps make available the orally administered irinotecan. In this study the intravenous (given into the vein) formula of irinotecan will be given orally on days 1-5 and days 8-12. The dose of ZD1839 will be a fixed dose and will be administered orally on days 1-12. Each course of treatment will consist of 21 days. The administration of irinotecan on day 12 of course 1 and day 2 of course 2 will be an intravenous administration. All other doses and subsequent courses will consist of an orally administered dose.	http://clinicaltrials.gov/ct2/show/NCT00132158 - Retrieved October 2011	St. Jude Children's Research Hospital	AstraZeneca; National Institutes of Health (NIH)	Currently recruiting	Primary Bone Cancer-Stage IV; Osteosarcoma-Stage IV
13	5	http://clinicaltrials.gov/ct2/show/NCT00134030	A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy - A Phase III Intergroup Study	This randomized phase III trial is studying combination chemotherapy followed by surgery and two different combination chemotherapy regimens with or without PEG-interferon alfa-2b to compare how well they work in treating patients with osteosarcoma.	http://clinicaltrials.gov/ct2/show/NCT00134030 - Retrieved October 2011	Children's Oncology Group	National Cancer Institute; University College London Hospitals	Currently recruiting	Primary Bone Cancer-Stage IV; Osteosarcoma-Stage IV
14	6	http://clinicaltrials.gov/ct2/show/NCT00179816	High-Dose Chemotherapy With Tandem Peripheral Blood Stem Cell (PBSC) Rescue for the Treatment of High-Risk Pediatric Solid Tumors.	This study uses a double autologous peripheral blood stem cell rescue (PBSC) following dose-intensive chemotherapy for the treatment of high-risk pediatric solid tumors.	http://clinicaltrials.gov/ct2/show/NCT00179816 - Retrieved October 2011	Children's Memorial Hospital		Currently recruiting	Ewing's Sarcoma
15	7	http://clinicaltrials.gov/ct2/show/NCT00186992	Image Guided Radiotherapy for the Treatment of Musculoskeletal Tumors: A Phase II Prospective Evaluation of Radiation-related Treatment Effects	Researchers at St. Jude Children's Research Hospital are looking for more effective ways to deliver radiation therapy to pediatric tumors of the bone and soft tissues. The goal of the study is to improve local control of musculoskeletal tumors with image-guided radiation therapy (IGRT) while minimizing radiation related side effects. IGRT uses computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) images to precisely define tumor location and to carefully plan radiation treatment. This approach allows doctors to deliver highly conformal radiation therapy to the tumor while protecting nearby healthy normal tissues.	http://clinicaltrials.gov/ct2/show/NCT00186992 - Retrieved October 2011	St. Jude Children's Research Hospital	Lance Armstrong Foundation	Currently recruiting	Ewing's Sarcoma
16	8
17	9	http://clinicaltrials.gov/ct2/show/NCT00335751	Glucose Metabolic Response by PET/CT to Sarcoma Treatments	This clinical trial is studying how well PET scan combined with CT scan evaluates treatment response in patients undergoing treatment for bone cancer or soft tissue sarcoma.	http://clinicaltrials.gov/ct2/show/NCT00335751 - Retrieved October 2011	University of California, Los Angeles	National Cancer Institute	Currently recruiting	Primary Bone Cancer-Stage IV
18	10	http://clinicaltrials.gov/ct2/show/NCT00346164	Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age	This phase III trial is studying observation to see how well it works compared with radiation therapy, combination chemotherapy, and/or surgery in treating patients with soft tissue sarcoma.	http://clinicaltrials.gov/ct2/show/NCT00346164 - Retrieved October 2011	Children's Oncology Group	National Cancer Institute	Currently recruiting	Primary Bone Cancer-Stage IV; Osteosarcoma-Stage IV; Chondrosarcoma-Stage IV
19	11	http://clinicaltrials.gov/ct2/show/NCT00496522	Phase II Evaluation of Proton Beam Therapy for Skull Base Chondrosarcoma	Refer to clinical trial website.	http://clinicaltrials.gov/ct2/show/NCT00496522 - Retrieved October 2011	M.D. Anderson Cancer Center		Currently recruiting	Chondrosarcoma
20	12	http://clinicaltrials.gov/ct2/show/NCT00556881	A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents and Young Adults With Treatment Refractory Cancer	This phase I trial is studying the side effects and best dose of ipilimumab in treating children, adolescents, and young adults with advanced or refractory solid tumors,	http://clinicaltrials.gov/ct2/show/NCT00556881 - Retrieved October 2011	National Cancer Institute		Currently recruiting	Primary Bone Cancer-Stage IV
21	13	http://clinicaltrials.gov/ct2/show/NCT00638898	Pilot Study of High-Dose Chemotherapy With Busulfan, Melphalan, and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplant in Advanced Stage and Recurrent Tumors	This clinical trial is studying how well giving busulfan, melphalan, and topotecan hydrochloride together with a stem cell transplant works in treating patients with newly diagnosed or relapsed solid tumor.	http://clinicaltrials.gov/ct2/show/NCT00638898 - Retrieved October 2011	City of Hope Medical Center		Currently recruiting	Primary Bone Cancer-Stage IV
22	14	http://clinicaltrials.gov/ct2/show/NCT00678769	Phase I Study of IMC-A12 (NSC# 742460) In Combination With Temsirolimus (CCI-779)(NSC# 683864) in Patients With Advanced Cancers	The goal of this clinical research study is to find the highest tolerable dose combination of IMC-A12 and temsirolimus that can be given to patients with advanced or metastatic cancer. Researchers will look at safety of the study drugs, and whether the study dosing schedule is tolerated by participants. Researchers will also perform biomarker tests to study how IMC-A12 and temsirolimus affect genes (material in the cells passed from parent to child that gives the child certain traits or characteristics) or proteins (the building blocks of cells) found in the blood.	http://clinicaltrials.gov/ct2/show/NCT00678769 - Retrieved October 2011	M.D. Anderson Cancer Center	National Cancer Institute	Currently recruiting	Sarcoma-Advanced or Metastatic
23	15	http://clinicaltrials.gov/ct2/show/NCT00689195	Evaluation of Curcumin Formulation, and Ashwagandha Root Powder Extract in the Management of Advanced High Grade Osteosarcoma"	Curcumin as well as the ashwagandha extract are ingredients from traditional indian medicine and have been shown to be potent anti-cancer compounds in laboratory as well as animal studies. This study will test the safety and efficacy of a curcumin formulation and the ashwagandha extract in high grade relapsed or metastatic osteosarcoma where no other second line chemotherapy is being given. The pharmacokinetics will be studied along with response as measured on CT scans and PET scans as well as the quality of life and any toxicity.	http://clinicaltrials.gov/ct2/show/NCT00689195 - Retrieved October 2011	Tata Memorial Hospital	Pharmanza Herbals Pvt Limited (PHPL)	Currently recruiting	Bone Cancer-Advanced or Metastatic
24	16	http://clinicaltrials.gov/ct2/show/NCT00691236	Evaluation of Zoledronic Acid as a Single Agent and as an Adjuvant to Chemotherapy in the Management of High Grade Osteosarcoma	Refer to clinical trial website.	http://clinicaltrials.gov/ct2/show/NCT00691236 - Retrieved October 2011	Tata Memorial Hospital		Currently recruiting	Primary Bone Cancer-Stage IV; Osteosarcoma-Stage IV
25	17	http://clinicaltrials.gov/ct2/show/NCT00713037	Hypoxia-PET and IMPT Dose Painting in Patients With Chordomas: A Pilot Study	Before radiation treatment is given to treat chordomas, CT and MRI scans are used to create a three dimensional picture of the tumor using x-rays. The CT and MRI scans are used to determine the size and location of the area that will receive radiation treatment. The purpose of this research study is to see if combining the images from the FMISO-PET scan and the CT and MRI scans in radiation treatment planning changes the size and location of the area that will receive radiation treatment when compared to planning the radiation treatment with CT and MRI scans alone.	http://clinicaltrials.gov/ct2/show/NCT00713037 - Retrieved October 2011	Massachusetts General Hospital		Currently recruiting	Chordoma
26	18	http://clinicaltrials.gov/ct2/show/NCT00720174	A Phase ½ Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma	This phase I/II trial is studying the side effects and best dose of IMC-A12 given together with doxorubicin hydrochloride and to see how well they work in treating patients with unresectable, locally advanced, or metastatic soft tissue sarcoma.	http://clinicaltrials.gov/ct2/show/NCT00720174 - Retrieved October 2011	University of Chicago	National Cancer Institute	Currently recruiting	Primary Bone Cancer-Stage IV; Osteosarcoma-Stage IV
27	19	http://clinicaltrials.gov/ct2/show/NCT00797602	A Clinical Outcomes Protocol of Proton Beam Radiation Therapy for Chordomas and/or Chondrosarcomas of the Base of Skull and/or Spine	Refer to clinical trial website.	http://clinicaltrials.gov/ct2/show/NCT00797602 - Retrieved October 2011	University of Florida		Currently recruiting	Chondrosarcoma
28	20	http://clinicaltrials.gov/ct2/show/NCT00802880	Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma	The purpose of this study is to determine the overall best tumor response rate to dacarbazine given until disease progression as assessed by RECIST criteria, CT and clinical exams in patients with metastatic sarcomas.	http://clinicaltrials.gov/ct2/show/NCT0080288 - Retrieved October 2011	Washington University School of Medicine		Currently recruiting	Primary Bone Cancer-Stage IV; Osteosarcoma-Stage IV
29	21	http://clinicaltrials.gov/ct2/show/NCT00813423	Autophagic Modulation With Anti-Angiogenic Therapy in Patients With Advanced Malignancies: A Phase I Trial of Sunitinib and Hydroxychloroquine	This phase I trial is studying the side effects and best dose of sunitinib when given together with hydroxychloroquine in treating patients with advanced solid tumors that have not responded to chemotherapy.	http://clinicaltrials.gov/ct2/show/NCT00813423 - Retrieved October 2011	University of Medicine and Dentistry New Jersey	National Cancer Institute	Currently recruiting	Bone Cancer-Advanced or Metastatic
30	22	http://clinicaltrials.gov/ct2/show/NCT00824083	Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment	The purpose of the study is to assess the functional outcome, quality of life and late sequelae in a representative sample of 1100 long-term survivors of Ewing sarcoma and to build a unique clinical and functional data pool of the underlying cohort of 3000 Ewing sarcoma patients with a follow-up of 3 decades.	http://clinicaltrials.gov/ct2/show/NCT00824083 - Retrieved October 2011	University Hospital Muenster	German Federal Ministry of Education and Research	Currently recruiting	Ewing's Sarcoma
31	23	http://clinicaltrials.gov/ct2/show/NCT00831844	A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, IND #100947, NSC #742460) in Children With Relapsed/Refractory Solid Tumors	This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors	http://clinicaltrials.gov/ct2/show/NCT00831844 - Retrieved October 2011	Children's Oncology Group	National Cancer Institute		Ewing's Sarcoma
32	24	http://clinicaltrials.gov/ct2/show/NCT00840047	Methionine PET/CT Studies In Patients With Cancer	Refer to clinical trial website.	http://clinicaltrials.gov/ct2/show/NCT00840047 - Retrieved October 2011	Methionine PET/CT Studies In Patients With Cancer		Currently recruiting	Ewing's Sarcoma
33	25	http://clinicaltrials.gov/ct2/show/NCT00841152	A National, Prospective, Randomized, Multicenter, Controlled Head-to-Head Comparison of Bioactive Glass and Beeta-Tricalcium Phosphate as Bone Graft Substitute in Filling of Contained Bone Defects	This study is designed to perform a head-to-head comparison of two synthetic ceramic bone graft substitutes, bioactive glass (BAG) and beeta-tricalcium phosphate (TCP), in filling of contained bone defects following surgical evacuation of benign bone tumor or tumor-like conditions. Based on the investigators' previous preclinical research and an ongoing single-center RCT on bioactive glass filling, the investigators expect BAG filling to be more efficient compared to TCP in promotion of defect healing and functional recovery after surgery.	http://clinicaltrials.gov/ct2/show/NCT00841152 - Retrieved October 2011	Turku University Hospital		Currently recruiting	Primary Bone Cancer-Stage IV
34	26	http://clinicaltrials.gov/ct2/show/NCT00887809	Phase II Trial Of Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes	The purpose of this study is to test whether an experimental drug called bevacizumab given together with gemcitabine and docetaxel, a standard chemotherapy regimen for sarcoma, can help sarcoma patients. This trial will examine what effects, good and/or bad the combination of gemcitabine, docetaxel and bevacizumab has on sarcoma.	http://clinicaltrials.gov/ct2/show/NCT00887809 - Retrieved October 2011	Memorial Sloan-Kettering Cancer Center	Genentech	Currently recruiting	Malignant Fibrous Histiocytoma
35	27	http://clinicaltrials.gov/ct2/show/NCT00923351	A Pilot Study of Tumor Vaccination and R-hIL-7 Following Standard Multimodality Therapy in Patients With High Risk Pediatric Solid Tumors	Refer to clinical trial website.	http://clinicaltrials.gov/ct2/show/NCT00923351 - Retrieved October 2011	National Cancer Institute		Currently recruiting	Ewing's Sarcoma
36	28	http://clinicaltrials.gov/ct2/show/NCT00949325	Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas	The purpose of this study is to identify a safe dosing regimen for the combination of Torisel and liposomal doxorubicin in patients with recurrent sarcoma. A secondary purpose of the study is to determine how effective this combination is for the treatment of recurrent sarcoma.	http://clinicaltrials.gov/ct2/show/NCT00949325 - Retrieved October 2011	Sidney Kimmel Comprehensive Cancer Center	National Comprehensive Cancer Network; Wyeth is now a wholly owned subsidiary of Pfizer	Currently recruiting	Primary Bone Cancer-Stage IV; Ewing's Sarcoma-Stage IV; Osteosarcoma-Stage IV; Chondrosarcoma-Stage IV
37	29	http://clinicaltrials.gov/ct2/show/NCT00987636	Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma	Refer to clinical trial website.	http://clinicaltrials.gov/ct2/show/NCT00987636 - Retrieved October 2011	University Hospital Muenster		Currently recruiting	Primary Bone Cancer-Stage IV; Ewing's Sarcoma-Stage IV; Osteosarcoma-Stage IV
38	30	http://clinicaltrials.gov/ct2/show/NCT01004861	A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients With Advanced, Incurable, Solid Tumors in Which the Target Kinases Are Linked to Disease Pathophysiology	PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity. The primary objective of this study is to evaluate the safety and pharmacokinetics of orally administered PLX3397 in patients with advanced, incurable, solid tumors in which these target kinases are linked to disease pathophysiology. These tumors include, but are not limited to, acute myelogenous leukemia (Flt3), gastrointestinal stromal tumor and neurofibromatosis-1 (Kit), and glioma, breast cancer, prostate cancer, multiple myeloma, Hodgkin lymphoma, and osteosarcoma (Fms/CSF-1). The secondary objective is to measure the pharmacodynamic activity of PLX3397 via plasma and urine biomarkers of Fms activity.	http://clinicaltrials.gov/ct2/show/NCT01004861 - Retrieved October 2011	Plexxikon		Currently recruiting	Osteosarcoma-Advanced or Metastatic
39	31	http://clinicaltrials.gov/ct2/show/NCT01016015	A Phase II Study of Temsirolimus (CCI-779, NSC 683864) and IGF-1 Receptor Antibody Cixutumumab (IMC-A12, NSC 742460) in Patients With Metastatic Sarcomas	This phase II trial is studying how well giving temsirolimus together with cixutumumab works in treating patients with locally advanced, metastatic, or recurrent soft tissue sarcoma or bone sarcoma.	http://clinicaltrials.gov/ct2/show/NCT01016015 - Retrieved October 2011	Memorial Sloan-Kettering Cancer Center	National Cancer Institute	Currently recruiting	Primary Bone Cancer-Stage IV
40	32	http://clinicaltrials.gov/ct2/show/NCT01047878	Genomic Analysis of Pediatric Bone Tumors (Other Title: Pediatric Bone Tumor Biology Study)	To determine whether gene expression analysis of primary tumor samples before and after chemotherapy are predictive of long-term survival in pediatric patients with bone sarcomas (Ewings sarcoma (ES) and Osteosarcoma(OS)).	http://clinicaltrials.gov/ct2/show/NCT01047878	Stanford University		Currently recruiting	Ewing's Sarcoma
41	33	http://clinicaltrials.gov/ct2/show/NCT01050296	Molecular Analysis Of Solid Tumors	This study will prospectively characterize the molecular, cellular and genetic properties of primary and metastatic neuroblastoma, osteosarcoma,retinoblastoma, Ewing sarcoma family of tumors and soft tissue sarcomas. These cell isolates will be used for gene expression array analysis, genomic analysis by [SNP]single nucleotide polymorphism chip, array [CGH]comparative genomic hybridization and next generation sequencing, and [TEM] transmission electron microscopy analysis. Additionally cell lines and orthotopic xenografts will be created from the obtained tumor specimens.	http://clinicaltrials.gov/ct2/show/NCT01050296 - Retrieved October 2011	St. Jude Children's Research Hospital		Currently recruiting	Ewing's Sarcoma
42	34	http://clinicaltrials.gov/ct2/show/NCT01106872	A Pilot Study Targeting Angiogenesis Using Bevacizumab Combined With Chemotherapy and Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas	The purpose of this study is to test the combination of the chemotherapy drugs Gemcitabine, bevacizumab, and docetaxel with valproic acid to treat patients with metastatic sarcoma. Valproic acid is used by people who have seizures to prevent seizures from happening; however, its use in cancer is investigational. This study will help define the proper dosing of this valproic acid. We will assess the safety of valproic acid with the combination of the above chemotherapy drugs and check for possible side effects. Valproic acid may improve the function of the chemotherapy drugs against the cancer.	http://clinicaltrials.gov/ct2/show/NCT01106872 - Retrieved October 2011	University of Iowa	Genentech	Currently recruiting	Sarcoma-Advanced or Metastatic
43	35	http://clinicaltrials.gov/ct2/show/NCT01112800	Markers of Anthracycline-Related Cardiac Muscle Injury	Refer to clinical trial website.	http://clinicaltrials.gov/ct2/show/NCT01112800 - Retrieved October 2011	St. Jude Children's Research Hospital		Currently recruiting	Ewing's Sarcoma
44	36	http://clinicaltrials.gov/ct2/show/NCT01139346	Phase I Study of Oral Darinaparsin in Advanced Solid Tumors	This study is a Phase I, dose escalation trial of oral darinaparsin for the treatment of advanced solid tumors. Eligible patients could have received any amount of previous therapy	http://clinicaltrials.gov/ct2/show/NCT01139346 - Retrieved October 2011	ZIOPHARM		Currently recruiting	Sarcoma-Advanced or Metastatic
45	37	http://clinicaltrials.gov/ct2/show/NCT01154452	A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas	This randomized phase I/II clinical trial is studying the side effects and best dose of RO4929097 when given together with GDC-0449 and to see how well they work in treating patients with advanced or metastatic sarcoma.	http://clinicaltrials.gov/ct2/show/NCT01154452 - Retrieved October 2011	Memorial Sloan-Kettering Cancer Center	National Cancer Institute	Currently recruiting	Primary Bone Cancer-Stage IV; Chondrosarcoma - Stage IV
46	38	http://clinicaltrials.gov/ct2/show/NCT01154816	A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias	This phase II trial is studying the side effects of and how well MLN8237 works in treating young patients with relapsed or refractory solid tumors or leukemia.	http://clinicaltrials.gov/ct2/show/NCT01154816 - Retrieved October 2011	Children's Oncology Group	National Cancer Institute	Currently recruiting	Ewing's Sarcoma
47	39	http://clinicaltrials.gov/ct2/show/NCT01155258	Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors.	This phase I trial is studying the side effects and best dose of giving temsirolimus and vinorelbine ditartrate together in treating patients with unresectable or metastatic solid tumors.	http://clinicaltrials.gov/ct2/show/NCT01155258 - Retrieved October 2011	USC/Norris Comprehensive Cancer Center	Wyeth is now a wholly owned subsidiary of Pfizer	Currently recruiting	Sarcoma-Advanced or Metastatic
48	40	http://clinicaltrials.gov/ct2/show/NCT01169584	A Phase I, Open-Label, Dose Escalation Study of JX-594 (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Administered by Intratumoral Injection in Pediatric Patients With Unresectable Refractory Solid Tumors.	This is a Phase I, open-label, dose-escalation trial in pediatric patients with advanced/metastatic, unresectable solid tumors refractory to standard therapy and/or the patient does not tolerate standard therapies. Tumors are likely to include neuroblastoma, lymphoma, Wilms' tumor, rhabdomyosarcoma, Ewing's sarcoma, osteosarcoma, non-rhabdomyosarcoma soft tissue sarcomas, and malignant peripheral nerve sheath tumors. Benign tumors are excluded. These tumor types were selected because evidence of biological activity was observed in cancer cells lines and ex vivo infected primary human tissue samples, specifically pediatric cancer types such as sarcomas and neuroblastomas.	http://clinicaltrials.gov/ct2/show/NCT01169584 - Retrieved October 2011	Jennerex Biotherapeutics	Solving Kids Cancer	Currently recruiting	Bone Cancer-Advanced or Metastatic
49	41	http://clinicaltrials.gov/ct2/show/NCT01174537	Clinical Application of Intravenous New Castle Disease Virus - HUJ Oncolytic Virus in the Treatment of Advanced Glioblastoma Multiforme, Soft and Bone Sarcomas and Neuroblastoma Patients, Resistant to Conventional Anti- Cancer Modalities	Patients with specific metastatic cancers who failed prior therapeutic regimes will be treated with NDV for at least a year or until disease progression. The study will measure progression-free disease and posits that it will be extended.	http://clinicaltrials.gov/ct2/show/NCT01174537 - Retrieved October 2011	Hadassah Medical Organization		Currently recruiting	Osteosarcoma - Stage IV
50	42	http://clinicaltrials.gov/ct2/show/NCT01175109	Multicenter Phase I Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma	This is a multi-center study to assess the safety and to determine the maximum tolerated dose of the combination of imatinib and LBH589 in patients with newly diagnosed and recurrent chordoma. For the recurrent population, those patients that do not require immediate surgical resection will be eligible. Patients will be treated with 4 cycles, followed by surgical resection if possible. If indicated, surgery may take place prior to the completion of 4 cycles.	http://clinicaltrials.gov/ct2/show/NCT01175109 - Retrieved October 2011	Deric M Park MD		Currently recruiting	Chordoma
51	43	http://clinicaltrials.gov/ct2/show/NCT01176981	Assessing the Safety, Feasibility, Cost Effectiveness and Patient Satisfaction of Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma	The primary purpose of this study is to determine the safety and feasibility of delivering HDMTX in an outpatient setting.	http://clinicaltrials.gov/ct2/show/NCT01176981 - Retrieved October 2011	The Hospital for Sick Children		Currently recruiting	Primary Bone Cancer-Stage IV; Osteosarcoma-Stage IV
52	44	http://clinicaltrials.gov/ct2/show/NCT01182753	Randomised Trial of Proton vs. Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcoma of the Skull Base, Clinical Phase III Study	The study is a prospective randomised clinical phase III trial. Proton therapy is the gold standard in the treatment of low and intermediate grad chondrosarcomas of the skull base. However, high-LET beams such as carbon ions theoretically offer biologic advantages by enhanced biologic effectiveness in slow-growing tumors. Up until now it was impossible to compare two different particle therapies, i.e. proton and carbon ion therapy directly with each other. The aim of this study is to find out, whether the biological advantages of carbon ion therapy mentioned above can also be clinically confirmed.	http://clinicaltrials.gov/ct2/show/NCT01182753 - Retrieved October 2011	University of Heidelberg		Currently recruiting	Chondrosarcoma
53	45	http://clinicaltrials.gov/ct2/show/NCT01182779	Randomised Trial of Proton vs. Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base -Clinical Phase III Study-	This study is a prospective randomised clinical phase III trial. The primary objective of this study is to evaluate, if the innovative therapy (carbon ion irradiation) in chordomas is superior to the standard proton treatment with respect to the local-progression free survival (LPFS).	http://clinicaltrials.gov/ct2/show/NCT01182779 - Retrieved October 2011	University of Heidelberg		Currently recruiting	Chordoma
54	46	http://clinicaltrials.gov/ct2/show/NCT01198184	Safety and Efficacy of RO4929097 in Combination With Temsirolimus: A Pharmacokinetic and Pharmacodynamic Phase I Study in Patients With Advanced Solid Tumours With an Expansion of Cohort With Patients With Recurrent/Metastatic Endometrial and Renal Cell Cancers	This phase I trial is studying the side effects and best dose of giving RO4929097 and temsirolimus together in treating patients with advanced solid tumors.	http://clinicaltrials.gov/ct2/show/NCT01198184 - Retrieved October 2011	Princess Margaret Hospital, Canada	National Cancer Institute	Currently recruiting	Sarcoma-Advanced or Metastatic
55	47	http://clinicaltrials.gov/ct2/show/NCT01204450	A Multi-center Phase I Trial of Temsirolimus in Combination With Valproic Acid in Children and Adolescents With Multiply Relapsed Pediatric Solid Tumors	This phase I trial is studying the side effects and the best dose of temsirolimus when given together with valproic acid in treating young patients with relapsed neuroblastoma, bone sarcoma, or soft tissue sarcoma.	http://clinicaltrials.gov/ct2/show/NCT01204450 - Retrieved October 2011	UNC Lineberger Comprehensive Cancer Center	National Cancer Institute	Currently recruiting	Ewing's Sarcoma
56	48	http://clinicaltrials.gov/ct2/show/NCT01210209	GENEWING - A Genome Wide Association Study in Ewing Sarcoma	This research study is looking at blood samples collected from patients with Ewing sarcoma and their relatives	http://clinicaltrials.gov/ct2/show/NCT01210209 - Retrieved October 2011	Institut Curie		Currently recruiting	Ewing's Sarcoma
57	49	http://clinicaltrials.gov/ct2/show/NCT01222767	Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy	This is a phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients with Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy to determine the antitumor activity of Zalypsis.	http://clinicaltrials.gov/ct2/show/NCT01222767 - Retrieved October 2011	PharmaMar		Currently recruiting	Bone Cancer-Advanced or Metastatic
58	50	http://clinicaltrials.gov/ct2/show/NCT01231906	A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma	This randomized phase III trial is studying combination chemotherapy in treating patients with non-metastatic extracranial Ewing sarcoma.	http://clinicaltrials.gov/ct2/show/NCT01231906 - Retrieved October 2011	Children's Oncology Group	National Cancer Institute	Currently recruiting	Primary Bone Cancer-Stage IV; Ewing's Sarcoma-Stage IV; Osteosarcoma-Stage IV
59	51	http://clinicaltrials.gov/ct2/show/NCT01242072	A Phase I Study of Intravenous (IV) Palifosfamide-tris Administered in Combination With IV Etoposide and IV Carboplatin in Patients With Malignancies for Which Etoposide and Carboplatin Are an Appropriate Choice	This an an open-label study to define the safety profile and the maximum tolerated dose and confirm the clinical effective dose of palifosfamide-tris given intravenously in combination with etoposide and carboplatin in a wide range of cancers which etoposide and carboplatin are normally given. Once the maximum dose of palifosfamide-tris is determined,a Phase II study using the 3 agents combined will begin.	http://clinicaltrials.gov/ct2/show/NCT01242072 - Retrieved October 2011	ZIOPHARM		Currently recruiting	Primary Bone Cancer-Stage IV; Osteosarcoma-Stage IV
60	52	http://clinicaltrials.gov/ct2/show/NCT01258634	A Pilot Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response	Refer to clinical trial website.	http://clinicaltrials.gov/ct2/show/NCT01258634 - Retrieved October 2011	University of Chicago		Currently recruiting	Primary Bone Cancer-Stage IV; Osteosarcoma-Stage IV
61	53	http://clinicaltrials.gov/ct2/show/NCT01267955	A Phase 2 Study of GDC-0449 in Patients With Advanced Chondrosarcomas	This phase II trial is studying how well GDC-0449 works in treating patients with advanced chondrosarcomas.	http://clinicaltrials.gov/ct2/show/NCT01267955 - Retrieved October 2011	Institut Bergonié	National Cancer Institute	Currently recruiting	Chondrosarcoma
62	54	http://clinicaltrials.gov/ct2/show/NCT01288573	A Phase 1/2 Combined Dose Ranging and Randomised, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells Into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilisation Regimens Alone in Paediatric Patients, Aged 2 to <18 Years, With Solid Tumours Eligible for Autologous Transplants.	Refer to clinical trial website.	http://clinicaltrials.gov/ct2/show/NCT01288573 - Retrieved October 2011	Genzyme		Currently recruiting	Ewing's Sarcoma
63	55	http://clinicaltrials.gov/ct2/show/NCT01310816	A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma	IPI-926 is an inhibitor of the hedgehog pathway. IPI-926 may improve therapeutic outcomes in patients with Chondrosarcoma.	http://clinicaltrials.gov/ct2/show/NCT01310816 - Retrieved October 2011	Infinity Pharmaceuticals		Currently recruiting	Bone Cancer-Advanced or Metastatic
64	56	http://clinicaltrials.gov/ct2/show/NCT01313884	A Phase II Pilot Study of Cyclophosphamide, Doxorubicin, Vincristine Alternating With Irinotecan and Temozolomide in Patients With Newly Diagnosed Metastatic Ewing's Sarcoma	The outcome of patients with metastatic Ewings Sarcoma is poor with current standard of care chemotherapy, with less than 30% survival. Based on recent encouraging pediatric literature we have designed this trial to improve the outcome of patients with metastatic Ewings sarcoma using Irinotecan and Temozolomide in addition to standard chemotherapy.	http://clinicaltrials.gov/ct2/show/NCT01313884 - Retrieved October 2011	Stanford University	Amgen	Currently recruiting	Ewing's Sarcoma
65	57	http://clinicaltrials.gov/ct2/show/NCT01325558	A Phase I, Open-Label, Multi-center, Competitive Enrollment and Dose-escalation Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors	This is a Phase I, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-836 in combination with standard of care gemcitabine in participants who have locally advanced or metastatic solid tumors. The purpose of this study is to determine the maximum tolerated dose (MTD), and to assess the safety and pharmacokinetic profile of ALT-836 given with gemcitabine. The clinical benefit, progression-free survival and overall survival of study participants will also be assessed.	http://clinicaltrials.gov/ct2/show/NCT01325558 - Retrieved October 2011	Altor Bioscience Corporation		Currently recruiting	Sarcoma-Advanced or Metastatic
66	58	http://clinicaltrials.gov/ct2/show/NCT01330966	A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma	The purpose of this study is to determine the effectiveness and safety of single agent pazopanib in subjects with chondrosarcoma.	http://clinicaltrials.gov/ct2/show/NCT01330966 - Retrieved October 2011	ACORN Research, LLC	GlaxoSmithKline	Currently recruiting	Chondrosarcoma
67	59	http://clinicaltrials.gov/ct2/show/NCT01331135	Sirolimus in Combination With Metronomic Therapy in Children With Recurrent and Refractory Solid Tumors: A Phase I Study	Refer to clinical trial website.	http://clinicaltrials.gov/ct2/show/NCT01331135 - Retrieved October 2011	Emory University	Children's Healthcare of Atlanta	Currently recruiting	Ewing's Sarcoma
68	60	http://clinicaltrials.gov/ct2/show/NCT01336803	Pilot Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI	The goal of our project is to establish a novel, non-invasive, immediately clinically applicable imaging test for the differentiation of bone sarcomas (osteosarcomas and Ewing sarcomas) and osteomyelitis.	http://clinicaltrials.gov/ct2/show/NCT01336803 - Retrieved October 2011	Stanford University		Currently recruiting	Chondrosarcoma
69	61	http://clinicaltrials.gov/ct2/show/NCT01344356	Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors	This study will evaluate the local control rates as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of benign and malignant head and neck tumors.	http://clinicaltrials.gov/ct2/show/NCT01344356 - Retrieved October 2011	St. John's Mercy Research Institute, St. Louis		Currently recruiting	Chondrosarcoma
70	62	http://clinicaltrials.gov/ct2/show/NCT01346124	Phase II Study of High Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of Skull	There are two types of external radiation treatments; proton beam and photon beam radiation. What type of therapy participants will receive will depend upon the location of their tumor. Standard treatment would involve receiving either proton or photon radiation delivered by a three dimensional (3-D) conformal radiation technique. 3-D conformal radiation therapy is a technique where the beams of radiation used in the treatment are shaped to match the tumor in order to avoid damaging the healthy surrounding tissue. Standard treatment also may include photon radiation delivered by intensity modulated (IMRT) technique. In this research study we are using an investigational technique to deliver proton radiation therapy called intensity modulated proton radiation treatment (IMPT) which is used to target cancer while sparing healthy tissue. With IMPT (and standard IMRT), radiation intensity can be turned down during the treatment. This control over the intensity of the radiation dose has the potential to provide accuracy and allows us to more safely increase the amount of radiation delivered to the tumor. This accuracy may potentially reduce side effects that patients would normally experience with 3-D proton radiation therapy. Surgery is often an important component of the treatment for these tumors and may be integrated with the IMPT.	http://clinicaltrials.gov/ct2/show/NCT01346124 - Retrieved October 2011	Massachusetts General Hospital	M.D. Anderson Cancer Center; National Cancer Institute	Not yet recruiting	Chondrosarcoma
71	63	http://clinicaltrials.gov/ct2/show/NCT01347307	Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Spine Metastases and Primary Spine Tumors	This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of spine metastases and benign spine tumors.	http://clinicaltrials.gov/ct2/show/NCT01347307 - Retrieved October 2011	St. John's Mercy Research Institute, St. Louis		Currently recruiting	Chordoma
72	64	http://clinicaltrials.gov/ct2/show/NCT01407198	Phase I Study of Nilotinib Given With Radiation For Patients With High Risk Chordoma	The study drug, Nilotinib, is believed to slow down tumor growth by regulating a gene involved in cellular growth of chordoma cells. During this research study, subjects will also receive radiation therapy which is considered a standard treatment for advanced chordomas. It is hoped by adding nilotinib, the benefits of radiation therapy can be enhanced without adding significant toxicities; The purpose of this research study is to determine the safety of nilotinib when used in combination with radiation therapy, and the highest dose of nilotinib that can be given safely with radiation therapy	http://clinicaltrials.gov/ct2/show/NCT01407198 - Retrieved October 2011	Massachusetts General Hospital		Currently recruiting	Chordoma
73	65	http://clinicaltrials.gov/ct2/show/NCT01446809	The Effect of Antiangiogenic Therapy With Pazopanib Prior to Preoperative Chemotherapy for Subjects With Extremity Soft Tissue Sarcomas: A Randomized Study to Evaluate Response by Imaging	This randomized pilot clinical trial studies pazopanib hydrochloride followed by chemotherapy and surgery in treating patients with soft tissue sarcoma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes that are needed for cell growth and may also stop the growth of soft tissue sarcoma by blocking blood flow to the tumor. Giving pazopanib hydrochloride and chemotherapy before surgery may make the tumor smaller and reduce the amount of tissue that needs to be removed	http://clinicaltrials.gov/ct2/show/NCT01446809 - Retrieved October 2011	Fred Hutchinson Cancer Research Center	National Cancer Institute	Not yet recruiting	Chondrosarcoma - Stage IV
74	66	http://clinicaltrials.gov/ct2/show/NCT01130623	A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors	Refer to clinical trial website.	http://clinicaltrials.gov/ct2/show/NCT01130623 - Retrieved October 2011	National Cancer Institute		Currently recruiting	Bone Sarcoma-Advanced
75	67	http://clinicaltrials.gov/ct2/show/NCT00974545	A Phase II Clinical Trial of Angiotensin 1-7 For the Second or Third Line Treatment of Patients With Metastatic or Unresectable Sarcomas	This phase II trial is studying the side effects of therapeutic angiotensin-(1-7) and to see how well it works as second-line therapy or third-line therapy in treating patients with sarcoma that is metastatic or that cannot be removed by surgery.	http://clinicaltrials.gov/ct2/show/NCT00974545 - Retrieved October 2011	Wake Forest University	National Cancer Institute	Currently recruiting	Bone Cancer - Metastatic
76	68	http://clinicaltrials.gov/ct2/show/NCT00667342	A Study of Bevacizumab, a Humanized Monoclonal Antibody Against Vascular Endothelial Growth Factor (VEGF), in Combination With Chemotherapy for Treatment of Osteosarcoma	This study adopts a novel strategy for first-line treatment of osteosarcoma by combining chemotherapy with anti-angiogenic therapy using bevacizumab (Avastin®), a humanized monoclonal antibody against vascular endothelial growth factor (VEGF). Chemotherapy for localized disease comprises a 3-drug regimen (cisplatin, doxorubicin, and high-dose methotrexate). Chemotherapy for metastatic or unresectable disease comprises a cisplatin-based regimen that includes high-dose methotrexate, doxorubicin, ifosfamide, and etoposide.	http://clinicaltrials.gov/ct2/show/NCT00667342 - Retrieved October 2011	St. Jude Children's Research Hospital	Genentech; National Institutes of Health (NIH)	Currently recruiting	Bone Cancer - Metastatic
77	69	http://clinicaltrials.gov/ct2/show/NCT00580385	Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors	The purpose of this study is to investigate tumors in the laboratory to determine how and why they respond, or fail to respond to different drug therapies. This study will also investigate why high pressure develops within tumors and how this affects how well drugs work. We will also take blood samples before and/or after your procedure to measure biochemical factors that may help us predict the behavior of osteogenic sarcoma and other solid tumors.	http://clinicaltrials.gov/ct2/show/NCT00580385 - Retrieved October 2011	Memorial Sloan-Kettering Cancer Center	Hospital for Special Surgery, New York	Currently recruiting	Bone Cancer - Metastatic
78	70	http://clinicaltrials.gov/ct2/show/NCT01005043	Phase I/II Therapy Trial to Determine the Safety and Efficacy of Heavy Ion Radiotherapy in Patients With Osteosarcoma	The primary objectives of this trial are the determination of feasibility and toxicity of Heavy Ion Radiotherapy (C12) in patients with non-resectable osteosarcoma. Secondary endpoints are tumor response, disease free survival and overall survival. The aim is to improve outcome for patients with non-resectable osteosarcoma	http://clinicaltrials.gov/ct2/show/NCT01005043 - Retrieved October 2011	University of Heidelberg	Dietmar Hopp Stiftung	Not yet recruiting	Bone Cancer - Metastatic
79	71	http://clinicaltrials.gov/ct2/show/NCT00631631	Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine (L-MTP-PE) for High-risk Osteosarcoma	Refer to clinical trial website.	http://clinicaltrials.gov/ct2/show/NCT00631631 - Retrieved October 2011	Millennium Pharmaceuticals, Inc.		Currently recruiting	Bone Cancer - Metastatic
80	72	http://clinicaltrials.gov/ct2/show/NCT01091883	Phase IIIA Study Comparing the Safety and Effectiveness of MR Guided Focused Ultrasound and External Beam Radiation for Treatment of Metastatic Bone Tumors and Multiple Myeloma	The goal of this study is to collect comparative data on safety and efficacy of MR Guided Focused Ultrasound and External Beam Radiation for treatment of metastatic bone tumors or multiple myeloma	http://clinicaltrials.gov/ct2/show/NCT01091883 - Retrieved October 2011	Insightec		Currently recruiting	Bone Cancer - Metastatic
81	73	http://clinicaltrials.gov/ct2/show/NCT01085565	Phase II Study to Evaluate the Safety and Effectiveness of ExAblate MR Guided Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System	The goal of this prospective, non-randomized, single-arm, phase 2 study is to evaluate the safety and effectiveness of this treatment using this ExAblate conformal system in the treatment of pain resulting from metastatic bone tumors Up to Fifty (50) patients will be recruited in this feasibility study. The treated patients will be followed for 3-Months post their last treatment, patients with the standard contraindications to MRI examination, such as implanted metal devices (pacemakers, etc.), will be excluded.	http://clinicaltrials.gov/ct2/show/NCT01085565 - Retrieved October 2011	Insightec		Currently recruiting	Bone Cancer - Metastatic
82	74	http://clinicaltrials.gov/ct2/show/NCT00767819	Multicenter, Triple-arm, Single-stage, Phase II Trial to Determine the Preliminary Efficacy and Safety of RAD001 in Patients With Histological Evidence of Progressive or Metastatic Bone or Soft Tissue Sarcomas	The purpose of this multicenter, two-arm, exact binomial single-stage, phase II trial is to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tissue sarcoma.	http://clinicaltrials.gov/ct2/show/NCT00767819 - Retrieved October 2011	Novartis Pharmaceuticals		Currently recruiting	Bone Cancer - Metastatic
83	75	http://clinicaltrials.gov/ct2/show/NCT01223248	A Phase III Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy in Patients With Metastatic Cancer	The purpose of this study is to find out which way of giving high-dose radiation works best for treatment of cancer that has spread to bone, the spine, soft tissue, or lymph nodes. This study will look at the effects, good and/or bad, of giving 27 Gy in three fractions (3 days) or 24 Gy in one fraction (1 day) using image-guided intensity-modulated radiotherapy (IG-IMRT). IG-IMRT is radiation that is given directly to the cancer site and reduces the exposure to normal tissue. Currently there are no studies that compare the effects of giving radiation in either hypofractionated doses (higher total doses of radiation spread out over several treatment days) or a single-fraction dose (entire radiation dose given in one treatment session).	http://clinicaltrials.gov/ct2/show/NCT01223248 - Retrieved October 2011	Memorial Sloan-Kettering Cancer Center	University of Pisa	Currently recruiting	Bone Cancer - Metastatic
84	ICAN advises every patient and other interested person, after reviewing this clinical trials spreadsheet, to check out clinical trials directly at www.cancer.gov in case there are updates since the date of this posting. ICAN does not purport to provide medical advice or to indicate which trial is suitable for a certain patient. Please consult your medical oncology team and the principal investigator in charge of the trial in which you are interested for information most relevant to your specific medical situation and decision-making process.